Impact of Attention on Obsessive Thoughts Through THOUGHT (THOUGHTS)

January 14, 2026 updated by: Assistance Publique - Hôpitaux de Paris

Thoughts Content in OCD: What Links Between Mind Wandering and Obsessions

Impact of attention on obsessive through the THOUGHT-scale (Troublesome Human Obsessions and Untargeted General Habitual Thoughts Scale): a description of the content of thoughts according to the level of attention demanded by the environment in patients with obsessive disorder compulsive disorder (OCD) and patients without OCD" Validation of THOUGHTS.

Study Overview

Status

Completed

Detailed Description

We developed a scale (the THOUGHTS) dedicated to allow a subject to subjectively measure its level of mind wandering/daydreaming (and obsessions in case of OCD patients) during different everyday situations. This scale is developed for 15 years old or older students (high school, university). Indeed, common point in everyday life was easier to find in students than in workers where lifestyle can be very divergent according to the job type. Through this scale, we will first detect the situations the more associated with mind wandering/daydreaming in healthy subjects. To do that, we will first find the 50% and the 25% of the situations the most associated with mind wandering. This step will allow us to distinguish two types of situations: situations with high level of mind wandering/daydreaming vs. situations with low level of mind wandering/daydreaming. Then we will do the same analyses in OCD patients to see if situations of high level of mind wandering are the same in both groups. Finally, we will compare the level of obsessions in OCD patients in these two types of situations (linked with high vs. low mind wandering, as defined by healthy subject, OCD patients and both populations).

To make these analyses, we will recruit 40 young OCD people (still students) from only one center, all diagnosed through DSM-5 criteria by a same senior and experimented child and adolescent psychiatrist and 40 matched healthy subjects.

For OCD patients: all comorbidities will be allowed except those associated with hallucinations or delusions: schizophrenia or bipolar disorder will then not be allowed. Neurological disorders will not be allowed too. Y-BOCS or CY-BOCS will be get and analyzed to find if severity could influence our results.

Healthy controls: they will be recruited to be matched with the OCD patients. No psychiatric or neurologic disorder will be allowed. No psychotropic or neurologic treatment will be allowed.

Finally, in terms of statistics, we will use non parametric tests.

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Creteil
      • Créteil, Creteil, France, 94010
        • Albert Chenevier hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

40 OCD patients 40 matched healthy controls

Description

Inclusion Criteria:

For pathological patients:

  • Over the age of 15
  • Suffering from OCD (obsessive compulsive disorder)
  • All comorbidities are possible except schizophrenia, bipolarity and anorexia nervosa
  • Consultant or admitted to Albert Chenevier Hospital

For patients who are not affected by the disease:

  • Over 15 years of age
  • Consulted or admitted to GH Henri Mondor

Exclusion Criteria:

For pathological patients:

  • Refusal to participate by the patient (and/or legal representative in the case of minors)
  • Presence of schizophrenia, bipolar or anorexia nervosa

For patients who are free of these conditions:

  • Presence of psychiatric or neurological pathology
  • Refusal to participate on the part of the patient (and/or on the part of the legal representative in the case of minors)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the obsession level (as measured by the THOUGHTS-scale) in situations associated with high level mind wandering/daydreaming and situations associated with low level of mind wandering/daydreaming
Time Frame: metrics are measured only one time, directly after the subject accept to participate to the study.
demonstrate that in patients with OCD, the level of presence of obsessions is different during active and passive situations, using the THOUGHT questionnaire - scale.
metrics are measured only one time, directly after the subject accept to participate to the study.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
: Effect of OCD severity on the link between OCD and mind wandering/daydreaming
Time Frame: measured only one time, directly after the subject accept to participate to the study.
Separated OCD patients in 2 groups according to their YBOCS severity to see if obsessions replace mind wandering in the same manner (the same situation and at the same level)
measured only one time, directly after the subject accept to participate to the study.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 22, 2023

Primary Completion (Actual)

September 8, 2023

Study Completion (Actual)

September 8, 2023

Study Registration Dates

First Submitted

February 10, 2023

First Submitted That Met QC Criteria

July 5, 2023

First Posted (Actual)

July 13, 2023

Study Record Updates

Last Update Posted (Actual)

January 15, 2026

Last Update Submitted That Met QC Criteria

January 14, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • APHP220613

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obsessive Compulsive Disorder OCD

Subscribe